ClinicalTrials.gg
RecruitingNCT06657391Updated Oct 28, 2024

Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia

A Phase 2 interventional study of recombinant humanized anti-CD25 monoclonal antibody in Transfusion Dependent Thalassemia, sponsored by Rongrong Liu. Recruiting at 5 sites in China. Open to participants aged 3 Years to 20 Years. Per ClinicalTrials.gov, last updated 2024-10-28.

Sponsored by Rongrong Liu · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
3 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Thalassemia with a site in China — 12 open to participants now, 14 under way, none of them phase 3. Thalassemia · China.

Planned enrollment
3rd of 27
396 · median 30
Started
2024
with 7 others
Phase 2
9 of 32
4 open now
Primary completion
2027-09
later than 9 of 13 live
Registered
26th of 32
by date
Lead sponsor
2 of 32
Rongrong Liu

Among the 32 studies in Thalassemia with a site in China, this one is the 3rd largest by planned enrollment of the 27 interventional ones that give a count, is one of 8 that started in 2024, is one of 9 in phase 2, reaches primary completion later than 9 of the 13 other live ones, and was the 26th registered.

Thalassemia

252 studies on the registry are indexed under Thalassemia; 45 are open to participants now.

Browse Thalassemia studies →

Open to participants now

12 of the 32 studies in Thalassemia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Thalassemia studies recruiting now, 8 (28%) set no upper age limit and 18 (62%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.

This study: 3 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Thalassemia with a site in China, or all of them as a file.
02

Study summary

Graft-versus-host disease (GVHD) is a major factor affecting the efficacy and quality of life of alternative donor transplantation in thalassemia major (TM), severely limiting the clinical application of alternative donor transplantation in TM.The purpose of this clinical trial is to evaluate whether recombinant humanized anti-CD25 monoclonal antibody is effective in preventing GVHD and its safety after haploidentical/matched unrelated donor hematopoietic stem cell transplantation. The main questions it aims to answer are:

  • Does recombinant humanized anti-CD25 monoclonal antibody reduce the incidence of GVHD disease after haploidentical/matched unrelated donor hematopoietic stem cell transplantation?
  • What medical problems will participants experience when using the recombinant humanized anti-CD25 monoclonal antibody? What is the quality of life after 2 years follow-up? In this clinical trail, participants will be randomly assigned to the intervention group or the control group by researchers in a 2:1 ratio. The intervention group will be given recombinant humanized anti-CD25 monoclonal antibody (1mg/Kg) combined with the standard GVHD prophylaxis after transplantation, while the control group will only receive the standard GVHD prophylaxis. The incidence of GVHD after transplantation in the two groups will be observed. The main evaluation is the clinical efficacy of recombinant humanized anti-CD25 monoclonal antibody in preventing aGVHD.
03

Conditions studied

  • Transfusion Dependent Thalassemia

Browse trials for

04

Who can participate

Ages eligible
3 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with transfusion-dependent thalassemia;
  • patients who are planning to receive matched unrelated donor hematopoietic stem cell transplantation (MUD-) or HLA haploidentical donor hematopoietic stem cell transplantation (HID-HSCT);
  • physical condition score (Lansky/ score) ≥ 70%;
  • patients (or legal guardians) voluntarily participate in the study and sign the form

Exclusion criteria

Exclusion Criteria:

  • patients with HLA-matched hematopoietic stem cell donors and willing to receive HLA-matched hematopoietic stem cell transplantation;
  • patients with known infectious diseases such as , , AIDS, syphilis, human T-lymphotropic virus, etc.;
  • patients with serious active bacterial, viral, fungal, malaria or parasitic infections;
  • patients with deficiency diseases;
  • patients with a history of malignant tumors or current malignant tumors;
  • patients with important organ diseases or abnormal laboratory tests, including but not limited to: 1) patients with cirrhosis, liver fibrosis or active hepatitis, and/or abnormal liver function tests ( (ALT) and aspartate aminotransferase (AST) ≥2.5×; alkaline phosphatase ≥2.5×ULN); 2) patients with heart disease, or (LVEF) \<60%, or severe iron deposition in the heart; 3) kidney disease, or blood creatinine ≥1.5×ULN with \<30% of normal level; 4) patients with endocrine dysfunction;
  • patients with uncorrected bleeding disease;
  • patients with severe mental illness (such as severe depression, schizophrenia, etc.) or cognitive dysfunction (dementia, delirium, etc.), which are unable to cooperate with the study;
  • peripheral blood white blood cell (WBC) count \<3×10\^9/L or count \<100×10\^9/L;
  • patients having received thalidomide treatment within the past 3 months;
  • patients having received any type of gene and/or cell therapy in the past;
  • patients with severe allergies;
  • female patients who are pregnant, breastfeeding, or planning to become pregnant within 1 year of participating in this trial;
  • patients who are participating in other clinical trials;
  • other situations that are not suitable for participation in this clinical trial as assessed by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
396 participants (estimated)

Study arms

  • Experimental
    intervention group

    The intervention group will receive 4 doses of recombinant humanized anti-CD25 monoclonal antibody (Sunshine Guojian Pharmaceutical(Shanghai) Co.,Ltd.) on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.

    Drug: recombinant humanized anti-CD25 monoclonal antibody

  • No intervention
    control group

    The control group will receive no treatment at the same time points.

Interventions

  • Drugrecombinant humanized anti-CD25 monoclonal antibody

    The intervention group received 4 doses of recombinant humanized anti-CD25 monoclonal antibody on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.

06

What researchers measure

Primary outcomes

  1. Grade III-IV aGVHD

    the incidence of grade III-IV aGVHD within 100 days after HID-HSCT/MUD-HSCT was compared between the intervention group and the control group.

    Time frame: within 100 days after HID-HSCT/MUD-HSCT

Secondary outcomes

  1. Grade II-IV aGVHD

    the incidence of grade II-IV aGVHD within 100 days after HID-HSCT/MUD-HSCT was compared between the intervention group and the control group.

    Time frame: within 100 days after HID-HSCT/MUD-HSCT

  2. Chronic graft-versus-host disease (cGVHD)

    The incidence of cGVHD after HID-HSCT/MUD-HSCT was compared between the intervention group and the control group.

    Time frame: 2 years

  3. Overall survival (OS)

    Comparison of 2-year OS between the intervention group and the control group.

    Time frame: 2 years

  4. Thalassemia-free survival (TFS)

    comparison of the 2-year TFS between the intervention group and the control group.

    Time frame: 2 years

  5. Transplantation-related mortality (TRM)

    comparison of the 2-year TRM between the intervention group and the control group.

    Time frame: 2 years

  6. Transplantation-related complications

    comparison of the 2-year transplantation-related complications between the intervention group and the control group.

    Time frame: 2 years

  7. Infection

    comparison of the infection during the transplantation between the intervention group and the control group.

    Time frame: 2 years

  8. Immune reconstitution

    comparison of the immune reconstitution after transplantation between the intervention group and the control group.

    Time frame: 2 years

  9. Quality of life

    comparison of the quality of life between the intervention group and the control group by using the Pediatric Quality of Life Inventory Version 4.0 (PedsQL4.0) scale. The scales are comprissed of parallel self-report and parent proxy-report formats: 1. Self-report includes ages 8 to 12, 13 to 18, and 18 to 25, with a total of 23 items. 2. Parent proxy-report assesses parent's perceptions of their child's health-related quality of life. Parent proxy-report (ages 5 to 7) has 23 items, and Parent proxy-report (ages 2 to 4) has 21 items. A 5-point response scale is utilized across self-report for ages and parent proxy-report (0 = never a problem; 1 = almost never a problem; 2 = sometimes a problem; 3 = often a problem; 4 = almost always a problem). Items are reverse-scored and linearly transformed to a 0 to 100 scale (0 = 100, 1 = 75, 2 = 50, 3 =25, 4 = 0), so that higher scores indicate better health-related quality of life.

    Time frame: 2 years

  10. Adverse events

    comparison of the occurrence of adverse events between the intervention group and the control group.

    Time frame: 2 years

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.

Of 26 phase 2 interventional studies under Thalassemia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 67. This study's planned 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2024
First posted
Oct 24, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Oct 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06657391
Lead sponsor
Rongrong Liu
Responsible party
Rongrong Liu (consultant; professor, First Affiliated Hospital of Guangxi Medical University) — Sponsor-investigator
First posted
Oct 24, 2024
Start date
Oct 1, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 28, 2024

Study contacts

Rongrong Liu
Contact
liurongrong@stu.gxmu.edu.cn
+86 0771 5356510

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion